[Skip to Content]
[Skip to Content Landing]
March 7, 2012

The Role of 5α-Reductase Inhibition in Men Receiving Testosterone Replacement Therapy

Author Affiliations

Author Affiliations: Department of Medicine, Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas; and Dallas Veterans Affairs Medical Center, Dallas, Texas.

JAMA. 2012;307(9):968-970. doi:10.1001/jama.2012.259

Testosterone has a variety of well-known effects including bone accrual, building and maintaining muscle mass, and promoting erectile function and libido.1 Of the 5 mg of testosterone manufactured daily by the testes, about 6% to 8% is metabolized by 5α-reductase to make 0.3 mg of dihydrotestosterone (DHT).2 Local conversion of testosterone to DHT by 5α-reductase in the skin and prostate can create locally high concentrations of the potent androgen DHT. Dihydrotestosterone stimulates prostate growth and may promote scalp hair loss. 5α-Reductase inhibition is the principal treatment for benign prostatic hypertrophy but the ramifications of treatment with drugs that inhibit this enzyme on the effects of androgen on the many tissues it influences is incompletely understood.

First Page Preview View Large
First page PDF preview
First page PDF preview